title: Restoration of endocrine and ovarian function after stopping GnRH antagonist treatment in goats.
abstract: We have tested if the high number of unfertilized ova and degenerated embryos found in superovulated goats previously treated with GnRH antagonist can be related to a prolongation of gonadotrophin down-regulation and/or alterations in follicular function during the period of administration of the superovulatory treatment, around 4 days after the end of the antagonist treatment. A total of 15 does were treated with intravaginal progestagen sponges and daily injections of 0.5mg of the GnRH antagonist Antarelix for 6 days, while 5 does acted as controls receiving saline. During the antagonist treatment, the mean plasma LH concentration was lower in treated than control goats (0.5 +/- 0.2 versus 0.7 +/- 0.5 ng/ml, P < 0.0005 ); however, the FSH levels remained unaffected (0.8 +/- 0.4 versus 0.8 +/- 0.5 ng/ml). In this period, treated does also showed an increase in the number of small follicles with 2-3 mm in size ( 10.7 +/- 0.7 versus 8.4 +/- 0.6, P < 0.05), and a decrease in both the number of follicles > or =4 mm in size ( 5.0 +/- 0.3 versus 6.8 +/- 0.5, P < 0.005) and the secretion of inhibin A (120.9 +/- 10.7 versus 151.6 +/- 12.6 pg/ml, P < 0.05). After cessation of the antagonist treatment, there was an increase in LH levels in treated goats from the day after the last Antarelix injection (Day 1), so that LH levels were the same as controls on Day 3 (0.6 +/- 0.1 versus 0.6 +/- 0.2 ng/ml). However, there were even greater numbers of small follicles than during the period of antagonist injections (15.4 +/- 0.6 in treated versus 8.9 +/- 0.7 in control, P < 0.0005 ). Moreover, the number of > or =4 mm follicles and the secretion of inhibin A remained lower in treated goats (3.9 +/- 0.3 follicles and 84.4 +/- 7.0 pg/ml versus 5.4 +/- 0.5 follicles, P < 0.05 and 128.9 +/- 14.2 pg/ml, P < 0.05 ). These results indicate that pituitary secretion of gonadotrophins is restored shortly after the end of antagonist treatment, but activity of ovarian follicles is affected.
authors.affiliation: Departamento de Reproducción Animal INIA, Avda. Puerta de Hierro s/n, 28040 Madrid, Spain. bulnes@inia.es
authors.forename: A
authors.initials: A
authors.lastname: Gonzalez-Bulnes
authors.forename: A
authors.initials: A
authors.lastname: Lopez-Sebastian
authors.forename: R M
authors.initials: RM
authors.lastname: Garcia-Garcia
authors.forename: A
authors.initials: A
authors.lastname: Veiga-Lopez
authors.forename: C J H
authors.initials: CJ
authors.lastname: Souza
authors.forename: A S
authors.initials: AS
authors.lastname: McNeilly
mesh_terms: D000282:Administration, Intravaginal; D000818:Animals; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006041:Goats / Q000502:physiology*; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D006728:Hormones / Q000502:physiology*; D007265:Inhibins / Q000378:metabolism; D007986:Luteinizing Hormone / Q000097:blood; D009842:Oligopeptides / Q000008:administration & dosage; D006080:Ovarian Follicle / Q000502:physiology; D010053:Ovary / Q000502:physiology*; D011372:Progestins / Q000008:administration & dosage; D013480:Superovulation
chemical_list: D006728:Hormones; D009842:Oligopeptides; D011372:Progestins; C422362:inhibin A; D007987:Gonadotropin-Releasing Hormone; D007265:Inhibins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; C084350:antarelix